Setmelanotide

MC4R (the melanocortin-4 receptor) sits at the center of the brain's satiety circuit. When the leptin-melanocortin pathway signals through it normally, you feel full. In rare inherited conditions like POMC, PCSK1, or LEPR deficiency, a single gene defect breaks that pathway upstream, so the receptor never receives its stop-eating signal. The result is severe, early-onset obesity driven by extreme, hard-to-control hunger (hyperphagia). Setmelanotide activates MC4R directly to replace the missing signal. These are monogenic disorders, not the common polygenic obesity most people have.

Imcivree (setmelanotide) is FDA-approved for chronic weight management in patients aged 6 and older, later extended to children as young as 2, with obesity caused by POMC deficiency, PCSK1 deficiency, LEPR deficiency, or Bardet-Biedl syndrome, confirmed by genetic testing. That is the entire label. It is not approved for common obesity, and trials have not shown meaningful weight loss in people without these specific genetic defects. Anyone marketing it as a general weight-loss shot is misrepresenting it.

Completely different target. Semaglutide and tirzepatide are incretin (GLP-1 and GIP) agonists that slow gastric emptying and boost insulin. Setmelanotide ignores the incretin system entirely and instead activates MC4R in the hypothalamus, the receptor at the end of the leptin-melanocortin hunger pathway. GLP-1 drugs work across a broad population; setmelanotide only helps when the melanocortin pathway itself is broken by a specific gene defect. Different receptor, different patient, different purpose.

The most common effects are skin hyperpigmentation, injection-site reactions, nausea, and darkening of existing moles or freckles. The pigmentation happens because setmelanotide is a melanocortin agonist with some off-target activity at MC1R on skin melanocytes, the same receptor Melanotan II hits to produce a tan. It is expected rather than a sign of harm, though new or changing moles should be evaluated. The label also carries warnings for disturbances in sexual arousal, depression and suicidal ideation, and skin reactions, so it is used under medical supervision.

It is a once-daily subcutaneous injection, usually taken in the morning in the abdomen, thigh, or upper arm with sites rotated. Imcivree comes as a ready-to-use 10 mg/mL solution, so there is no reconstitution. Dosing starts low (often 2 mg, lower in young children) and is titrated to response and tolerability up to a maximum of 3 mg per day. It should be stored refrigerated.

They are cousins, not the same drug. Both are melanocortin agonists, which is why both can darken skin. But Melanotan II is non-selective (it hits MC1R, MC3R, MC4R, and MC5R) and is used as a research tanning and libido compound with no FDA approval. Setmelanotide is MC4R-selective, pharmaceutical grade, FDA-approved, and used to treat defined genetic obesity disorders. Same receptor family, very different selectivity and regulatory standing.